Cargando…
Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells
The overall five-year survival rate for late-stage patients of ovarian cancer is below 29% due to disease recurrence and drug resistance. Cancer stem cells (CSCs) are known as a major contributor to drug resistance and recurrence. Accordingly, therapies targeting ovarian CSCs are needed to overcome...
Autores principales: | Lee, Heejin, Kwon, Oh-Bin, Lee, Jae-Eon, Jeon, Yong-Hyun, Lee, Dong-Seok, Min, Sang-Hyun, Kim, Jun-Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072797/ https://www.ncbi.nlm.nih.gov/pubmed/33923707 http://dx.doi.org/10.3390/cells10040918 |
Ejemplares similares
-
The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis
por: Motawea, Amira, et al.
Publicado: (2022) -
Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly
por: Zhou, Yeping, et al.
Publicado: (2022) -
Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial
por: Kountouras, Jannis, et al.
Publicado: (2020) -
The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs
por: Hussain, Zahid, et al.
Publicado: (2018) -
Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness
por: Lee, Heejin, et al.
Publicado: (2020)